Grants and Contributions:
This project will contribute to establishing Biovectra as a world leader in biologics development and production, grow the firm's market share and drive innovation and growth in Atlantic Canada Biotech Community. The project allows Biovectra to be positioned in the COVID-19 response while it continues to deliver on its significant economic, innovation and public benefit for Atlantic Canada. This project anticipates the creation of 200 new full-time jobs and will maintain 500 full-time jobs within Canada.
The Amendment has been completed to reduce the contribution amount from $37.5M to $21.1M. This is a partially repayable contribution.
-Encourage R&D that will accelerate technology transfer and commercialization of innovative products, processes and services;-Facilitate the growth and expansion of firms in Canada;-Attract and retain large scale investments to Canada; and-Advance industrial research, development and technology demonstration through collaboration between academia, non-profit organizations and the private sector.